ANGIOGENIC & TISSUE RESEARCH

TB-500: Thymosin β4 in Tissue Repair Research

Velox Peptides Research Team·Published May 2026·7 min read
CAS Number
77591-33-4
Peptide Class
Actin-binding peptide
Parent Protein
Thymosin β4 (43-aa)
HPLC Purity
≥99% (batch-verified)
For in vitro research use only. This summary of the preclinical literature is provided for scientific reference, not medical advice. TB-500 (Thymosin β4) is not for human or veterinary consumption.

What is TB-500?

TB-500 is a synthetic peptide based on Thymosin β4 (Tβ4), a naturally occurring 43-amino-acid protein found in nearly all mammalian cells and present in high concentrations in platelets and wound fluid. In research supply, “TB-500” refers to a synthetic preparation of the active actin-binding region of Thymosin β4, used as a reagent for studying the peptide’s role in cell motility and tissue remodelling.

Thymosin β4 is the principal G-actin–sequestering peptide in cells: it binds monomeric (globular) actin and helps regulate the balance between free actin monomers and the polymerised actin filaments that drive cell movement. This single biochemical property underlies much of the research interest in the peptide.

Mechanisms studied in preclinical models

Actin sequestration. By binding G-actin, Thymosin β4 maintains a reservoir of actin monomers that cells can rapidly mobilise to build the cytoskeletal structures needed for migration. In wound-healing models this is associated with faster keratinocyte and endothelial cell migration into the wound site.

Cell migration and angiogenesis. Preclinical studies have examined Thymosin β4’s association with endothelial cell migration, tube formation and the sprouting of new blood vessels (angiogenesis) — processes central to how tissue is repaired and re-vascularised in animal models.

Inflammation and remodelling signalling. The peptide has been studied for its association with reduced inflammatory signalling and modulation of extracellular-matrix remodelling in rodent injury models, although the precise receptor-level pathways remain an active area of investigation.

Why TB-500 is studied alongside BPC-157

TB-500 and BPC-157 are frequently studied together in tissue-repair research because they are associated with complementary mechanisms: BPC-157 with angiogenic and gastrointestinal-mucosal pathways (including VEGFR2/eNOS–NO signalling), and TB-500 with actin-driven cell migration. Researchers investigating multi-pathway repair models often pair the two to examine whether the combined profile differs from either peptide alone. The pairing is available as the BPC-157 & TB-500 research blend.

Velox Peptides supply information

Velox Peptides supplies TB-500 as a lyophilised powder at ≥99% HPLC-verified purity, third-party tested with a batch certificate of analysis available on request. For reconstitution volumes, see the reconstitution calculator. Supplied strictly as a research reagent for in vitro use.

References & further reading

  1. Goldstein AL, Hannappel E, Kleinman HK. “Thymosin β4: actin-sequestering protein moonlights to repair injured tissues.” Trends in Molecular Medicine, 2005.
  2. Malinda KM et al. “Thymosin β4 accelerates wound healing.” Journal of Investigative Dermatology, 1999.
  3. Sosne G et al. “Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators.” Experimental Eye Research, 2002.

Summaries are paraphrased from the peer-reviewed preclinical literature. For full source citations, email veloxpeps@gmail.com.

Frequently asked questions

What is TB-500?
TB-500 is a synthetic research peptide based on the actin-binding region of Thymosin Beta-4, a naturally occurring peptide involved in cell migration and tissue remodelling. Velox Peptides supplies it strictly for in vitro research use only.
How does TB-500 differ from Thymosin Beta-4?
Thymosin Beta-4 is the full-length 43-amino-acid parent peptide. TB-500 is a synthetic preparation of its active actin-binding region, used as a research reagent.
Why is TB-500 studied with BPC-157?
The two are associated with complementary tissue-repair mechanisms — BPC-157 with angiogenic and mucosal pathways, TB-500 with actin-driven cell migration — so researchers often study them together in repair models.
What purity is Velox Peptides TB-500?
TB-500 is HPLC-verified at a minimum of ≥99% purity, with batch documentation available on request.
Is TB-500 legal to buy in the UK?
Research peptides including TB-500 are legal to purchase in the UK for in vitro research purposes. They are not licensed medicines and not approved for human use. Velox Peptides supplies TB-500 solely as a research reagent.
Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.

All research summaries on this page are derived from publicly available peer-reviewed literature. Velox Peptides makes no therapeutic claims. For research use only.